Actavis inks key refinancing deal

Icelandic generic drugmaker Actavis has agreed to a debt refinancing deal with its lenders to slash its multibillion-euro debt load. Release | Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.